MM
Mahave, M.
2 papers · 38 citations · 2024–2024
Publications
2
Citations
38
Years
1
Publications
| Title | Year | Type | Citations |
|---|---|---|---|
|
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
|
2024 | Meeting Abstract | 38 |
|
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
|
2024 | Meeting Abstract | 0 |